- Email: [email protected]
Molecular Heterogeneity in Gastric Cancer: Genomic Approaches and Clinical Impact
Annals of Oncology 25 (Supplement 4): iv14, 2014 doi:10.1093/annonc/mdu297.4
special symposium: towards personalised medicine in gastric, pancreatic and liver cancer: from “omics” research to treatment MOLECULAR HETEROGENEITY IN GASTRIC CANCER: GENOMIC APPROACHES AND CLINICAL IMPACT
abstracts
P. Tan Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School Singapore, SINGAPORE
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv14/2240798 by guest on 24 October 2019
36IN
Gastric cancer (GC) is a leading cause of global cancer mortality. Prior research has shown that GC is a molecularly heterogeneous disease, with each patient’s tumor exhibiting distinct genetic and molecular profiles. However, few of these molecular differences currently impact on the clinical management of GC patients, with most patients today being treated with relatively uniform institutional protocols. In this talk, I will present and summarize recent progress from our group and others in integrating genomic and epigenomic profiles of GC patients, to identify new GC driver aberrations and discrete disease subgroups unified by common underlying molecular mechanisms. I will present evidence that the molecular heterogeneity of GC is indeed clinically relevant, impacting patient prognosis and response to therapy. Consideration of the underlying heterogeneity of GC should thus be an important factor in the evaluation of both standard and novel therapeutics in GC. Disclosure: The author has declared no conflicts of interest.
special symposium: towards personalised medicine in gastric, pancreatic and liver cancer: from “omics” research to treatment MOLECULAR HETEROGENEITY IN GASTRIC CANCER: GENOMIC APPROACHES AND CLINICAL IMPACT
abstracts
P. Tan Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School Singapore, SINGAPORE
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv14/2240798 by guest on 24 October 2019
36IN
Gastric cancer (GC) is a leading cause of global cancer mortality. Prior research has shown that GC is a molecularly heterogeneous disease, with each patient’s tumor exhibiting distinct genetic and molecular profiles. However, few of these molecular differences currently impact on the clinical management of GC patients, with most patients today being treated with relatively uniform institutional protocols. In this talk, I will present and summarize recent progress from our group and others in integrating genomic and epigenomic profiles of GC patients, to identify new GC driver aberrations and discrete disease subgroups unified by common underlying molecular mechanisms. I will present evidence that the molecular heterogeneity of GC is indeed clinically relevant, impacting patient prognosis and response to therapy. Consideration of the underlying heterogeneity of GC should thus be an important factor in the evaluation of both standard and novel therapeutics in GC. Disclosure: The author has declared no conflicts of interest.